Percentage of patients in each group achieving poor response to imatinib as defined by 1-log reduction by 6 months and 2-log reduction by 12 months
. | Failure to achieve a 1-log reduction in BCR-ABL by 6 mo . | Failure to achieve a 2-log reduction in BCR-ABL by 12 mo . |
|---|---|---|
| Overall IC50imatinib | ||
| Low, %, n = 36 | 14 | 22 |
| High, %, n = 26 | 8 | 23 |
| P | > .05 | > .05 |
| Overall Sokal score | ||
| Low, %, n = 28 | 7 | 14 |
| High, %, n = 31 | 16 | 12 |
| P | > .05 | > .05 |
| Low Sokal score only | ||
| Low IC50imatinib, %, n = 15 | 0 | 7 |
| High IC50imatinib, %, n = 13 | 15 | 33 |
| P | .013 | .032 |
. | Failure to achieve a 1-log reduction in BCR-ABL by 6 mo . | Failure to achieve a 2-log reduction in BCR-ABL by 12 mo . |
|---|---|---|
| Overall IC50imatinib | ||
| Low, %, n = 36 | 14 | 22 |
| High, %, n = 26 | 8 | 23 |
| P | > .05 | > .05 |
| Overall Sokal score | ||
| Low, %, n = 28 | 7 | 14 |
| High, %, n = 31 | 16 | 12 |
| P | > .05 | > .05 |
| Low Sokal score only | ||
| Low IC50imatinib, %, n = 15 | 0 | 7 |
| High IC50imatinib, %, n = 13 | 15 | 33 |
| P | .013 | .032 |